Neoleukin Therapeutics NLTX Stock
Neoleukin Therapeutics Price Chart
Neoleukin Therapeutics NLTX Financial and Trading Overview
| Neoleukin Therapeutics stock price | 3.49 USD |
| Previous Close | 0.75 USD |
| Open | 0.75 USD |
| Bid | 0 USD x 1800 |
| Ask | 0 USD x 800 |
| Day's Range | 0.74 - 0.75 USD |
| 52 Week Range | 0.38 - 1.34 USD |
| Volume | 46.05K USD |
| Avg. Volume | 173.3K USD |
| Market Cap | 31.69M USD |
| Beta (5Y Monthly) | 1.253169 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.5 USD |
NLTX Valuation Measures
| Enterprise Value | -39632740 USD |
| Trailing P/E | N/A |
| Forward P/E | -4.352941 |
| PEG Ratio (5 yr expected) | -0.1 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.3894737 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.762 |
Trading Information
Neoleukin Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.253169 |
| 52-Week Change | -26.00000000000000000000000000000000% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.34 USD |
| 52 Week Low | 0.38 USD |
| 50-Day Moving Average | 0.83 USD |
| 200-Day Moving Average | 0.66 USD |
NLTX Share Statistics
| Avg. Volume (3 month) | 173.3K USD |
| Avg. Daily Volume (10-Days) | 51.55K USD |
| Shares Outstanding | 42.83M |
| Float | 28.76M |
| Short Ratio | 1.97 |
| % Held by Insiders | 18.19% |
| % Held by Institutions | 40.39% |
| Shares Short | 229.62K |
| Short % of Float | 0.54% |
| Short % of Shares Outstanding | 0.54% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.0019% |
| Return on Equity (ttm) | -53.35% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -52003000 USD |
| Net Income Avi to Common (ttm) | -56410000 USD |
| Diluted EPS (ttm) | -0.98 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 83.44M USD |
| Total Cash Per Share (mrq) | 1.95 USD |
| Total Debt (mrq) | 11.68M USD |
| Total Debt/Equity (mrq) | 14.36 USD |
| Current Ratio (mrq) | 11.967 |
| Book Value Per Share (mrq) | 1.9 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -44549000 USD |
| Levered Free Cash Flow (ttm) | -25159250 USD |
Profile of Neoleukin Therapeutics
| Country | United States |
| State | WA |
| City | Seattle |
| Address | 188 East Blaine Street |
| ZIP | 98102 |
| Phone | 866 245 0312 |
| Website | https://www.neoleukin.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 12 |
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Q&A For Neoleukin Therapeutics Stock
What is a current NLTX stock price?
Neoleukin Therapeutics NLTX stock price today per share is 3.49 USD.
How to purchase Neoleukin Therapeutics stock?
You can buy NLTX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Neoleukin Therapeutics?
The stock symbol or ticker of Neoleukin Therapeutics is NLTX.
Which industry does the Neoleukin Therapeutics company belong to?
The Neoleukin Therapeutics industry is Biotechnology.
How many shares does Neoleukin Therapeutics have in circulation?
The max supply of Neoleukin Therapeutics shares is 2.35M.
What is Neoleukin Therapeutics Price to Earnings Ratio (PE Ratio)?
Neoleukin Therapeutics PE Ratio is 0.00000000 now.
What was Neoleukin Therapeutics earnings per share over the trailing 12 months (TTM)?
Neoleukin Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Neoleukin Therapeutics company belong to?
The Neoleukin Therapeutics sector is Healthcare.
Neoleukin Therapeutics NLTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}